We could show a significantly enhanced tumor outgrowth in Nr2f6−/− mice treated with a combination of CD4+ and CD8+ depleting antibodies when compared to the IgG2b-treated Nr2f6−/− control group (Supplementary Fig. 2F). This evidence concerns the gene NR2F6 and neoplasm.